Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing a 13% Increase Over the Prior Year
31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the…
News
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for…
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
– Topline Data Expected First Quarter 2023 – DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug….
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
— Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED)…
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Vistin Pharma ASA: Invitation to Q2 2022 conference call
Oslo, Norway, 11 August 2022 Vistin Pharma ASA will release its second quarter and YTD…
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
– FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for…
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
In line with corporate strategy update in April, ProQR to focus exclusively on the development…
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment…
Trevena Reports Second Quarter 2022 Results and Provides Business Update
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION…
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second…
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid…
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration…
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and…
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights
ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing…
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential…
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in…
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
— Strong cash position with $54.8 million of cash and cash equivalents as of June 30,…